#VisualAbstract: Neoadjuvant atezolizumab is not effective for node-positive HER2⁺ breast cancer
Click to read this study in the Journal of Clinical Oncology. ...
Click to read this study in the Journal of Clinical Oncology. ...
Patients with triple-negative breast cancer (TNBC) who harbor more than 40% tumor-infiltrating lymphocytes in their tumor respond well to neoadjuvant immune checkpoint blockade, results from...
Results from the second interim analysis of MONARCH 3 show that overall survival is numerically longer with abemaciclib plus a non-steroidal aromatase inhibitor (NSAI) versus placebo plus a ...
Click to read this study in The Lancet Oncology. ...
Click to read this study in JAMA Oncology. ...
Click to read this study in The Lancet Oncology. ...
Click to read this study in JAMA. ...
Click to read this study in JAMA Network Open. ...
Click to read this study in Journal of Clinical Oncology. ...
Click to read this study in The Lancet Oncology. ...
Click to read this study in JAMA Oncology. ...
In three MONALEESA phase 3 trials, addition of ribociclib to adjuvant endocrine therapy improved overall survival (OS) in post-menopausal patients with locally advanced/metastatic HR-positiv...
According to the first results of the EMERALD trial, elacestrant, the first oral selective estrogen receptor degrader, shows clinical benefit over standard endocrine therapy in patients with...
Primary analysis of the KEYNOTE-522 trial shows a statistically significant and clinically meaningful improvement in the event-free survival (EFS) of neoadjuvant pembrolizumab plus chemother...
A next-generation technology allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME). In the NeoTRIPaPDL1 trial,...
Although adjuvant therapy with CDK4/6 inhibitors has shown to benefit patients with advanced/metastatic HR-positive/HER2-negative breast cancer, the final analysis of the PALLAS trial shows ...
The use of multigene sequencing as a therapeutic decision tool improved the outcomes for patients with metastatic breast cancer when the genomic alterations identified were ranked in the I/I...
The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called ‘accelerated mutagenesis’, researchers unraveled the role of ASXL1 loss. Initial findings ...
Development of breast cancer-related lymphedema is not equally distributed between races. Black women experienced higher rates of breast cancer-related lymphedema than White women, results o...
The latest articles and insights from your colleagues in your specialty(ies) of choice.
Insights from the leaders in medical research, trending topics in clinical medicine, and perspectives from your colleagues.
Subscribe to our free Newsletters to receive weekly emails, and even get a laugh or two from our medical cartoons.